Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 4Leukemia 4Lymphoma, T-Cell, Cutaneous 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mycosis Fungoides 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Hematologic Diseases 1Dendritic Cell Sarcoma, Interdigitating 1Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7ofatumumab 4ibrutinib 4Rituximab 2KW-2478 2Dasatinib 2Alemtuzumab 2ziconotide 1sodium luminolate 1ruxolitinib 1oblimersen 1obinutuzumab 1mocetinostat 1milatuzumab 1ixekizumab 1fludarabine 1fenebrutinib 1baricitinib 1abexinostat 1Saline Solution 1Lenalidomide 1Hsp90 inhibitor KU757 1Etanercept 1Cyclophosphamide 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × B3(Fv)-PE38KDEL recombinant immunotoxin × Lymphoid × Clear all
NCT00077922 2018-01-23

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
15 enrolled 10 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡